Ketorolac is a nonsteroidal anti-inflammatory, or NSAID, drug used to treat moderately severe to acute pain.
Fresenius Kabi said it found the recalled lots contain carbon, silicon, oxygen and polyamides.
Giving patients the recalled drugs could cause serious, life-threatening effects, such as blood clots and lung tissue scarring.
Fresenius Kabi told its customers to immediately discontinue use of the affected lots and return them to the drugmaker.
The company didn’t say if it’s received any adverse event reports related to the recall.
Read the full news release here.
More articles on pharmacy:
Largest hydroxychloroquine study to date finds no benefit for COVID-19
NIH panel releases COVID-19 treatment, pharmaceutical intervention guidelines
How 13 drugmakers have responded to the COVID-19 pandemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
